Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034

Graft versus host disease (GVHD) is regarded as one of the primary causes of morbidity and mortality following hematopoietic stem cell transplantation. Up to 50% of patients who receive hematopoietic stem cell transplantation from an HLA-matched sibling may develop acute graft versus host disease (GVHD). In unmatched donors, the incidence is usually higher. Between 6% and 80% of people have chronic GVHD. And more than 10% of patients pass away from the condition. The graft versus host disease (GVHD) epidemiology forecast indicates a projected increase in diagnosed cases in the coming years, driven by rising allogeneic hematopoietic stem cell transplant (HSCT) procedures and improved diagnostic capabilities.

Graft Versus Host Disease (GVHD) Epidemiology Forecast Report Coverage

The “Graft Versus Host Disease (GVHD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of graft versus host disease (GVHD). It projects the future incidence and prevalence rates of Graft Versus Host Disease (GVHD) cases across various populations. The study covers age, gender, and type as major determinants of the graft versus host disease (GVHD) population. The report highlights patterns in the prevalence of graft versus host disease (GVHD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the graft versus host disease (GVHD) epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Graft Versus Host Disease (GVHD) Understanding: Disease Overview

Graft-versus-host disease (GVHD) can develop when donor immune cells attack the recipient's tissues because they perceive them as alien following an allogeneic stem cell or bone marrow transplant. It mainly affects the gastrointestinal tract, liver, and skin, causing symptoms like severe diarrhea, jaundice, and rashes.

There are two types of graft versus host disease (GVHD), namely, acute and chronic GVHD. Acute graft versus host disease (GVHD) happens within the first 100 days after a transplant, while chronic graft versus host disease (GVHD) develops later and has long-term systemic effects. Immune response intensity and donor-recipient genetic mismatch are two factors that affect how severe the condition is.

Graft Versus Host Disease (GVHD) Epidemiology Perspective

The graft versus host disease (GVHD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for the graft versus host disease (GVHD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for graft versus host disease (GVHD) and their trends. The graft versus host disease (GVHD) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The gastrointestinal (GI) tract, liver, and skin are typically affected by acute graft versus host disease (GVHD); these conditions affect 70%, 74%, and 44% of cases, respectively. Additionally, graft versus host disease (GVHD) may impair responsiveness to active immunization and impact the hematopoietic system, kidneys, eyes, and lungs.
• A study indicates that, in general, moderate to severe graft versus host disease (GVHD) has a higher mortality rate than mild disease. For grade C, the 5-year survival rate is 25%, while for grade 4, it is 5%.
• Some studies revealed that around 79,233 patients (76%) met the selection criteria out of the 104,313 patients who had an HLA-identical sibling donor HSCT, which were reported from 466 teams in 52 countries. There were 38,671 (49%) and 27,748 (35%), patients with acute graft versus host disease (GVHD) and chronic graft versus host disease (GVHD), respectively, among a total of 50,210 (63%) GVHD patients. Also, there were 29,023 (37%) patients reported with no graft versus host disease (GVHD) at all.
• Chronic graft versus host disease (GVHD) is the most frequent long-term complication following allogeneic hematopoietic cell transplantation (HCT), affecting approximately 10% to 50% of patients . It typically presents as a multi-organ disorder, with an average involvement of 3 or more organs, as per Lee, S. J. (2017).

Country-wise Graft Versus Host Disease (GVHD) Epidemiology Segment

The graft versus host disease (GVHD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of graft versus host disease (GVHD) varies between countries owing to the differences in factors such as cancer prevalence and genetic mutation, among others. In the United States, approximately 35-50% of recipients of hematopoietic stem cell transplants will experience acute graft versus host disease (GVHD). Due to the volume of transplants, it is estimated that 5500 patients will experience acute graft versus host disease (GVHD) annually.

Graft Versus Host Disease (GVHD): Treatment Overview

The goal of treating graft versus host disease (GVHD) is to maintain graft function while inhibiting the donor immune response. Corticosteroids, such as prednisone, are commonly used as first-line graft versus host disease (GVHD) therapeutics to reduce inflammation. Immunosuppressive drugs like calcineurin inhibitors (like tacrolimus and cyclosporine) or biologics (like ruxolitinib and IL-2 receptor blockers) may be used in steroid-refractory cases. Improving results requires supportive care, which includes infection prevention and symptom management. The severity and type (acute or chronic) of graft versus host disease (GVHD) determine the treatment strategy.

Key Questions Answered

• What are the key findings of graft versus host disease (GVHD) epidemiology in the 8 major markets?
• What will be the total number of patients with graft versus host disease (GVHD) across the 8 major markets during the forecast period?
• What was the country-wise graft versus host disease (GVHD) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of graft versus host disease (GVHD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of graft versus host disease (GVHD) during the forecast period of 2025-2034?
• What are the currently available treatments in the graft versus host disease (GVHD) market?
• What are the disease risks, signs, symptoms, and unmet needs of graft versus host disease (GVHD)?

Scope of the Graft Versus Host Disease (GVHD) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of graft versus host disease (GVHD) based on several factors.
• Graft Versus Host Disease (GVHD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The graft versus host disease (GVHD) report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.